vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Rumble Inc. (RUM). Click either name above to swap in a different company.
Rumble Inc. is the larger business by last-quarter revenue ($27.1M vs $15.0M, roughly 1.8× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -120.8%, a 122.6% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -10.5%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-31.7M). Over the past eight quarters, Rumble Inc.'s revenue compounded faster (15.2% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Rumble is a Canadian-American online video platform, web hosting, and cloud services business headquartered in Toronto, Canada, with its U.S. headquarters in Longboat Key, Florida. It was founded in 2013 by Chris Pavlovski, a Canadian technology entrepreneur. Rumble's cloud services business hosts Truth Social, and the video platform is popular among American conservative and far-right users. Rumble has been described as "alt-tech".
CSBR vs RUM — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $27.1M |
| Net Profit | $268.0K | $-32.7M |
| Gross Margin | 51.7% | 5.5% |
| Operating Margin | 1.2% | -131.1% |
| Net Margin | 1.8% | -120.8% |
| Revenue YoY | 11.5% | -10.5% |
| Net Profit YoY | -63.2% | 86.2% |
| EPS (diluted) | $0.02 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $27.1M | ||
| Q3 25 | $14.0M | $24.8M | ||
| Q2 25 | $12.4M | — | ||
| Q1 25 | $17.0M | $23.7M | ||
| Q4 24 | $13.5M | $30.2M | ||
| Q3 24 | $14.1M | $25.1M | ||
| Q2 24 | $14.0M | $22.5M | ||
| Q1 24 | $12.0M | $17.7M |
| Q4 25 | $268.0K | $-32.7M | ||
| Q3 25 | $-436.0K | $-16.3M | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $4.5M | $-2.7M | ||
| Q4 24 | $728.0K | $-236.8M | ||
| Q3 24 | $1.3M | $-31.5M | ||
| Q2 24 | $-109.0K | $-26.8M | ||
| Q1 24 | $-2.5M | $-43.3M |
| Q4 25 | 51.7% | 5.5% | ||
| Q3 25 | 42.9% | -1.8% | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | -26.7% | ||
| Q4 24 | 44.9% | -14.2% | ||
| Q3 24 | 49.7% | -45.4% | ||
| Q2 24 | 48.2% | -58.8% | ||
| Q1 24 | 34.7% | -79.5% |
| Q4 25 | 1.2% | -131.1% | ||
| Q3 25 | -3.8% | -113.6% | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | 26.4% | -153.5% | ||
| Q4 24 | 5.4% | -80.1% | ||
| Q3 24 | 9.5% | -131.0% | ||
| Q2 24 | -1.9% | -172.7% | ||
| Q1 24 | -21.4% | -197.4% |
| Q4 25 | 1.8% | -120.8% | ||
| Q3 25 | -3.1% | -65.7% | ||
| Q2 25 | -14.9% | — | ||
| Q1 25 | 26.4% | -11.2% | ||
| Q4 24 | 5.4% | -783.2% | ||
| Q3 24 | 9.3% | -125.9% | ||
| Q2 24 | -0.8% | -119.2% | ||
| Q1 24 | -21.1% | -244.1% |
| Q4 25 | $0.02 | $-0.13 | ||
| Q3 25 | $-0.03 | $-0.06 | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $0.31 | $-0.01 | ||
| Q4 24 | $0.05 | $-1.17 | ||
| Q3 24 | $0.09 | $-0.15 | ||
| Q2 24 | $-0.01 | $-0.13 | ||
| Q1 24 | $-0.19 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $237.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $274.8M |
| Total Assets | $30.2M | $336.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $237.9M | ||
| Q3 25 | $10.3M | $269.8M | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | $301.3M | ||
| Q4 24 | $2.8M | $114.0M | ||
| Q3 24 | $2.9M | $132.0M | ||
| Q2 24 | $2.6M | $154.2M | ||
| Q1 24 | $4.5M | $183.8M |
| Q4 25 | $4.2M | $274.8M | ||
| Q3 25 | $3.5M | $302.2M | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $5.5M | $339.6M | ||
| Q4 24 | $681.0K | $-63.1M | ||
| Q3 24 | $-332.0K | $166.1M | ||
| Q2 24 | $-1.9M | $192.7M | ||
| Q1 24 | $-2.1M | $210.7M |
| Q4 25 | $30.2M | $336.8M | ||
| Q3 25 | $30.5M | $367.2M | ||
| Q2 25 | $32.3M | — | ||
| Q1 25 | $30.6M | $391.1M | ||
| Q4 24 | $25.2M | $195.3M | ||
| Q3 24 | $24.9M | $217.2M | ||
| Q2 24 | $26.1M | $243.2M | ||
| Q1 24 | $26.8M | $263.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-29.4M |
| Free Cash FlowOCF − Capex | $-2.0M | $-31.7M |
| FCF MarginFCF / Revenue | -13.1% | -117.2% |
| Capex IntensityCapex / Revenue | 1.6% | 8.5% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-70.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-29.4M | ||
| Q3 25 | $600.0K | $-10.6M | ||
| Q2 25 | $6.9M | — | ||
| Q1 25 | $490.0K | $-14.5M | ||
| Q4 24 | $-283.0K | $-12.4M | ||
| Q3 24 | $311.0K | $-19.1M | ||
| Q2 24 | $-1.8M | $-21.7M | ||
| Q1 24 | $-919.0K | $-33.9M |
| Q4 25 | $-2.0M | $-31.7M | ||
| Q3 25 | $554.0K | $-12.0M | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | $-14.6M | ||
| Q4 24 | $-377.0K | $-12.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | $-1.8M | $-23.1M | ||
| Q1 24 | $-1.0M | $-34.3M |
| Q4 25 | -13.1% | -117.2% | ||
| Q3 25 | 4.0% | -48.6% | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | -61.7% | ||
| Q4 24 | -2.8% | -40.9% | ||
| Q3 24 | — | -79.5% | ||
| Q2 24 | -13.0% | -102.8% | ||
| Q1 24 | -8.4% | -193.3% |
| Q4 25 | 1.6% | 8.5% | ||
| Q3 25 | 0.3% | 5.7% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.7% | 0.1% | ||
| Q3 24 | 0.0% | 3.4% | ||
| Q2 24 | 0.0% | 6.1% | ||
| Q1 24 | 0.8% | 2.4% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
